
TNF-alpha, Mouse, mAb V1q
The monoclonal antibody V1q recognizes mouse tumor necrosis factor alpha (TNF-α). TNF-α is the
prototype cytokine of the family of TNF-related ligands, which are based on structural and functional
homologies. TNF-α is synthesized as type II transmembrane protein. TNF-α can be recognized by two
different membrane receptors, namely TNF-R1 and TNF-R2. TNF-α is present in a membrane-bound
(tmTNF) as well as soluble form (sTNF). The membrane-bound form of TNF-α is recognized by both
TNF receptors with high affinity, whereas the soluble form is recognized more superiorly by TNF-R1.
TNF-α is produced by many different cell types including macrophages, T lymphocytes, NK cells,
neutrophils and endothelial cells. Cells differ in the expression of the two TNF-receptors and sTNF
versus tmTNF, respectively.
TNF-α, a homotrimeric 17 kDa protein, is a potent mediator of inflammatory and metabolic functions.
TNF-α was originally detected as a highly cytotoxic cytokine for tumor cells, it causes tumor necrosis
in vivo and shows cytolytic activity against tumor cells in vitro. Furthermore, TNF-α has been implied
as central mediator in shock induced by gram negative micro-organisms. TNF-α induces on its turn
the production of many other cytokines. Furthermore, TNF-α has been found in inflammatory foci such
as synovial effusions in rheumatoid arthritis, systemic circulation in septic shock, parasitemia and
rejection of renal transplants. The monoclonal antibody V1q recognizes both natural and recombinant
TNF-α and shows neutralizing activity.
FS: Antibody V1q functions as a neutralizing antibody. The antibody was functionally tested by neutralization of the cytopathic effect of cytotoxin in the L929 TNF bioassay. The biological activity of the antibody can be defined as the concentration of V1q required to neutralize 100 U/ml of TNF/cytotoxin. (Ref.1)
You may be interested in…
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA